FDA scientific reviewers who have long experience with vaccine development are encouraged by the rapid rate of enrollment in the ongoing clinical trials for a #COVID19 vaccine.
They are looking forward to the completion of the trials so that they can evaluate data and decide whether to approve or authorize its use.
We at FDA recognize that we must build public trust so there is confidence in future decisions about vaccines for #COVID19. I am concerned when I see public surveys that many people will decline taking a vaccine.
FDA scientists will judge vaccine safety and effectiveness solely on the basis of good scientific data.
We are already starting to think about the meeting of our vaccine advisory committee on Oct 22. It will be conducted virtually and made available for public viewing.
The committee’s discussion and recommendations are not binding on FDA but will be important in our deliberations. Plus the public will be able to see the data that we have been asked to evaluate.
